Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients

Completed · Phase 4

Conditions studied: Immunosuppression, Stem Cell Transplant, Bone Marrow Transplant

In brief

Researchers are trying to learn more about using sublingual (absorption under the tongue) tacrolimus in blood and marrow transplant patients.

Key facts

Study ID

NCT04041219

Run by

Mayo Clinic

People needed

10

Starts

2019-06-17

Expected to finish

2019-10-08

Last updated by the study team

2020-08-07

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Individuals will be identified from within the adult allogeneic BMT program at Mayo Clinic in Rochester, Minnesota
• Adults prescribed tacrolimus for treatment or prevention of Graft Versus Host Disease (GVHD)

You may not qualify if…

• Vulnerable populations
• Patients with contraindications to tacrolimus, inclusive of hypersensitivity, history of posterior reversible encephalopathy syndrome or calcineurin-inhibitor induced thrombotic microangiopathy
• Lacking the capacity to consent in English and declining to participate in research

Where it is running

• Mayo Clinic in Rochester — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.